Your browser doesn't support javascript.
loading
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4ß-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Ngaimisi, E; Minzi, O; Mugusi, S; Sasi, P; Riedel, K-D; Suda, A; Ueda, N; Bakari, M; Janabi, M; Mugusi, F; Bertilsson, L; Burhenne, J; Aklillu, E; Diczfalusy, U.
Afiliación
  • Ngaimisi E; Department of Pharmacognosy, Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, PO Box 65013, Dar es Salaam, Tanzania Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospi
  • Minzi O; Department of Pharmacognosy, Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, PO Box 65013, Dar es Salaam, Tanzania.
  • Mugusi S; Department of Clinical Pharmacology, School of Medicine, Muhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania.
  • Sasi P; Department of Clinical Pharmacology, School of Medicine, Muhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania.
  • Riedel KD; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
  • Suda A; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Ueda N; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Bakari M; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania.
  • Janabi M; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania.
  • Mugusi F; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania.
  • Bertilsson L; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Burhenne J; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
  • Aklillu E; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Diczfalusy U; Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, C1: 74, SE-141 86 Stockholm, Sweden.
J Antimicrob Chemother ; 69(12): 3311-9, 2014 Dec.
Article en En | MEDLINE | ID: mdl-25096076
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Rifampin / Fármacos Anti-VIH / Benzoxazinas / Citocromo P-450 CYP3A / Citocromo P-450 CYP2B6 / Hidroxicolesteroles / Antituberculosos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Rifampin / Fármacos Anti-VIH / Benzoxazinas / Citocromo P-450 CYP3A / Citocromo P-450 CYP2B6 / Hidroxicolesteroles / Antituberculosos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Año: 2014 Tipo del documento: Article